BMY

  
 
 
Bristol-Myers Squibb Company

Dividend Growth

Min. Div. Growth Past 7 Yrs. ≥ 15%: 10.2
Rolling 4-Yrs Div. Growth Past 7 Yrs ≥ 15%: 0.9%
Years of Div. Growth ≥ 15: 51

Income Generation

Current Yield 4.7≥ 20-Yrs Treasury Yield 4.5
Total Dividends ≥ 20-Yrs Treasury Coupons in 5 Yrs

Sustainability

Debt-To-Equity 0.78 ≤ 0.45 
Last 12Months Cash Payout 0.38 ≤ 0.6 

Profitability

5-Yr Avg. Return-on-Equity 10.9≥ 15%
Last 12Months Return-on-Equity 0.0≥ 15%
Last 12Months Net Profit Margin 0.0≥ 10% 

Fair Value

Average 5-Yrs High Yield 3.9%
Current Price $50.9 ≤ High Yield Price $60.1
Average 5-Yrs Price-to-Earning (P/E) 21.6
Current Price $50.9 ≤ Average P/E Price N/A
Current Price $50.9 ≤ Fair Value $48.1 

Company Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Dividend

Revenue

Earning

Free Cash Flow